Economic impact of extended treatment with peginterferon α-2a and ribavirin for slow hepatitis C virologic responders

被引：17

作者：

Nakamura, J. ^{[1
]}

Toyabe, S. -I. ^{[1
]}

Aoyagi, Y. ^{[2
]}

Akazawa, K. ^{[1
]}

机构：

[1] Niigata Univ, Grad Sch Med & Dent Sci, Div Informat Sci & Biostat, Chuo Ku, Niigata 9518520, Japan

[2] Niigata Univ, Grad Sch Med & Dent Sci, Div Gastroenterol & Hepatol, Niigata, Japan

来源：

JOURNAL OF VIRAL HEPATITIS | 2008年 / 15卷 / 04期

关键词：

combination therapy; economic impact; extended treatment; peginterferon; ribavirin; slow virologic responders;

D O I：

10.1111/j.1365-2893.2007.00943.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

It is difficult to achieve a sustained virologic response from antiviral therapy for genotype 1 hepatitis C virus-infected patients without a sufficient virologic response in the early weeks after treatment. However, a recent study has reported on the effectiveness of an extended course of treatment with peginterferon alpha-2a plus ribavirin for slow virologic responders. The aim of this study was to evaluate the economic impact of an extended course of treatment. A Markov cohort model of hepatitis C was designed in order to demonstrate the clinical states, based on the assigned transition probabilities over 30 years. The slow virologic responders treated with an extended 72-week course of therapy could increase by 0.55 the quality-adjusted life years (=15.35-14.80) and reduce the lifetime cost by $2762 (=71 559-69 438) in comparison with those treated by the standard 48-week course. One-way sensitivity analyses did not change the cost-effectiveness. Therefore, the extended 72 weeks of treatment with peginterferon alpha-2a plus ribavirin for slow virologic responders could be cost-effective in comparison with the standard 48 weeks of treatment.

引用

页码：293 / 299

页数：7

共 36 条

[1] THE MARKOV PROCESS IN MEDICAL PROGNOSIS [J].

BECK, JR ;

PAUKER, SG .

MEDICAL DECISION MAKING, 1983, 3 (04) :419-458

[2] Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C [J].

Bennett, WG ;

Inoue, Y ;

Beck, JR ;

Wong, JB ;

Pauker, SG ;

Davis, GL .

ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) :855-+

[3] Natural history of compensated viral cirrhosis:: a prospective study on the incidence and hierarchy of major complications [J].

Benvegnù, L ;

Gios, M ;

Boccato, S ;

Alberti, A .

GUT, 2004, 53 (05) :744-749

[4] Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin [J].

Berg, T ;

von Wagner, M ;

Nasser, S ;

Sarrazin, C ;

Heintges, T ;

Gerlach, T ;

Buggisch, P ;

Goeser, T ;

Rasenack, J ;

Pape, GR ;

Schmidt, WE ;

Kallinowski, B ;

Klinker, H ;

Spengler, U ;

Martus, P ;

Alshuth, U ;

Zeuzem, S .

GASTROENTEROLOGY, 2006, 130 (04) :1086-1097

[5] Epidemiology of primary liver cancer [J].

Bosch, FX ;

Ribes, J ;

Borràs, J .

SEMINARS IN LIVER DISEASE, 1999, 19 (03) :271-285

[6] Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C [J].

Buti, M ;

Casado, MA ;

Fosbrook, L ;

Wong, JB ;

Esteban, R .

JOURNAL OF HEPATOLOGY, 2000, 33 (04) :651-658

[7] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C [J].

Davis, GL ;

Wong, JB ;

McHutchison, JG ;

Manns, MP ;

Harvey, J ;

Albrecht, J .

HEPATOLOGY, 2003, 38 (03) :645-652

[8] The association between hepatitis C infection and survival after orthotopic liver transplantation [J].

Forman, LM ;

Lewis, JD ;

Berlin, JA ;

Feldman, HI ;

Lucey, MR .

GASTROENTEROLOGY, 2002, 122 (04) :889-896

[9] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[10] Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].

Hadziyannis, SJ ;

Sette, H ;

Morgan, TR ;

Balan, V ;

Diago, M ;

Marcellin, P ;

Ramadori, G ;

Bodenheimer, H ;

Bernstein, D ;

Rizzetto, M ;

Zeuzem, S ;

Pockros, PJ ;

Lin, A ;

Ackrill, AM .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355

← 1 2 3 4 →